Cellosaurus cell line ADK-VR2 (CVCL

Cellosaurus ADK-VR2 (CVCL_E6J5)

[Text version]

Cell line name

ADK-VR2

Accession

CVCL_E6J5

Resource Identification Initiative

To cite this cell line use: ADK-VR2 (RRID:CVCL_E6J5)

Comments

Population: Southeast Asian; Filipino.
Doubling time: 34.88 hours (Direct_author_submission).
Omics: Genomics; Whole exome sequencing.
Omics: Transcriptomics; RNAseq.
Donor information: Established from a treatment-naive non-smoker patient (PubMed=36519016).
Miscellaneous: Doubling time and ethnic origin of patient from personal communication of Angelicola, Stefania.
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:10661; SDC4; Name(s)=SDC4-ROS1; Note=SDC4 exon 2 fused to ROS exon 32 (PubMed=36519016).

Disease

Lung adenocarcinoma (NCIt: C3512)

Species of origin

Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy

Children:

CVCL_E6J6 (ADK-VR2 AG143)

Sex of cell

Male

Age at sampling

46Y

Category

Cancer cell line

Publications

PubMed=36519016; DOI=10.21037/tlcr-22-163; PMCID=PMC9742620
Ruzzi F., Angelicola S., Landuzzi L., Nironi E., Semprini M.S., Scalambra L., Altimari A., Gruppioni E., Fiorentino M., Giunchi F., Ferracin M., Astolfi A., Indio V., Ardizzoni A., Gelsomino F., Nanni P., Lollini P.-L., Palladini A.
ADK-VR2, a cell line derived from a treatment-naive patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC.
Transl. Lung Cancer Res. 11:2216-2229(2022)

Entry history

Entry creation

10-Apr-2025

Last entry update

10-Apr-2025

Version number